A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma

NCT00362102 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Carcinoma

Interventions

DRUG: Cetuximab

Sponsor

Eli Lilly and Company